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Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Here, tofacitinib
safety and efficacy data from a long-term extension study in Japanese patients are presented.
Methods: Study A3921041 was a multi-centre, open-label, long-term extension study that included Japanese
patients who had participated in a prior Phase 2 or Phase 3 study of tofacitinib as monotherapy or with background
methotrexate. Patients received tofacitinib 5 mg twice daily (BID) or tofacitinib 10 mg BID. Dose adjustment of tofacitinib
during treatment period, and concomitant usage of disease-modifying antirheumatic drugs including methotrexate after
week 12 were permitted. Primary endpoints were adverse events, laboratory parameters and vital signs. Secondary
efficacy endpoints included American College of Rheumatology (ACR)20/50/70 response rates, Disease Activity Score
(DAS)28-4(erythrocyte sedimentation rate (ESR))<2.6 response rate (DAS-defined remission) and Health Assessment
Questionnaire-Disability Index (HAQ-DI) score. Safety and efficacy data were assessed throughout the study.
Results: A total of 486 patients were recruited and treated (1439.9 patient-years of exposure). 308 patients completed the study.
Median (range) duration of treatment in this extension study was 1185 (5–2016) days. 476 patients (97.9 %) experienced adverse
events; the majority of which (97.8 %) were of mild or moderate severity. The two most common treatment-emergent adverse
events were nasopharyngitis (n = 293, 60.3 %) and herpes zoster (n = 94, 19.3 %). For all tofacitinib-treated patients, the incidence
rate (patients with events per 100 patient-years) was 10.7 for serious adverse events, 3.3 for serious infections, 7.4 for herpes
zoster (serious and non-serious) and 1.2 for malignancies (excluding non-melanoma skin cancer). Mean changes from baseline
(start of the index study) in laboratory parameters were consistent with those seen in previously reported studies of tofacitinib.
ACR20/50/70 response rates, DAS-defined remission rates and HAQ-DI scores were sustained through to study completion.
Conclusions: Tofacitinib (with or without background methotrexate) demonstrated a stable safety profile and sustained efficacy
in Japanese patients with active rheumatoid arthritis. The risk of herpes zoster appears to be higher in Japanese patients treated
with tofacitinib than in the global population.
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In Japan current therapies for rheumatoid arthritis include
non-biologic and biologic disease-modifying antirheu-
matic drugs (DMARDs), which can be used alone or in
combination with other DMARDs. Methotrexate is the
most commonly prescribed DMARD, but its use can be
limited by inadequate efficacy, poor tolerability or
contraindication. Five tumour necrosis factor inhibitors
(infliximab, etanercept, adalimumab, golimumab and
certolizumab), an anti-interleukin-6 receptor antibody
(tocilizumab) and a selective co-stimulating modulator
(abatacept), are currently approved for patients with an
inadequate response to traditional DMARDs such as
methotrexate [1–3]. Each of these is an injectable, biologic
agent. There is currently no oral option available other
than tofacitinib for patients in need of therapy after failure
of conventional synthetic DMARDs. Therefore, tofaciti-
nib addresses an unmet need for therapeutic options
with alternative mechanisms of action, enabling oral
formulations.
Tofacitinib is a selective inhibitor of the Janus kinase
family and blocks intracellular signalling of multiple key
cytokines involved in the inflammatory cascade [4].
Tofacitinib has demonstrated efficacy and safety in the
treatment of active rheumatoid arthritis in global phase
II, phase III and long-term extension (LTE) studies, and
in two randomised, 12-week, phase II studies in Japanese
patients with rheumatoid arthritis [5–16].
Double-blind, randomised controlled trials represent
the standard approach in determining the short-term
safety and efficacy of therapy; however, agents used to
treat chronic conditions, such as rheumatoid arthritis,
must also demonstrate long-term safety and efficacy.
Here we report the safety and efficacy of tofacitinib in
Japanese patients in an LTE study, following their
participation in phase II and phase III index studies of
the drug.
Methods
Study design and treatment
Study A3921041 (NCT00661661) was a multi-centre,
open-label LTE study conducted at 56 centres in Japan.
The study was initiated on 18 April 2008 and included
patients who had participated in prior randomised phase
II or phase III index studies of tofacitinib in Japan. The
primary completion date was 25 December 2013.
The index studies investigated tofacitinib monotherapy
1–15 mg twice daily (BID) (A3921040, NCT00687193)
[16] or tofacitinib 1–10 mg BID in combination with
background methotrexate (A3921039, NCT00603512;
A3921044, NCT00847613) [12, 13]. All patients entering
the LTE study received initial treatment with oral tofaci-
tinib 5 mg BID. At the investigator’s discretion, the
tofacitinib dose could be increased to 10 mg BID (forinadequate response) or could be reduced from 10–
5 mg BID, or it could be temporarily discontinued. Pa-
tients who received tofacitinib 10 mg BID for a total of
12 weeks or more are classified herein as the 10 mg BID
group, while all other patients are referred to as the
5 mg BID group. The study was not designed for direct
statistical comparisons of tofacitinib dosing regimens.
This study was conducted in compliance with the
Declaration of Helsinki and the Good Clinical Practice
Guidelines established by the International Conference on
Harmonisation. The final protocols, amendments and
informed consent documentation were reviewed and
approved by the Institutional Review Boards and/or
Independent Ethics Committee of each study centre (see
Acknowledgements for details). All patients provided writ-
ten, informed consent.Patients
Patients were ≥20 years of age (there was no upper age
limit) and had completed participation in a prior rando-
mised phase II or phase III index study of tofacitinib for
the treatment of rheumatoid arthritis in Japan. Eligibility
criteria for the index studies have been reported elsewhere
[12, 13, 16]. Briefly, the key inclusion criteria of the index
studies were: diagnosis of rheumatoid arthritis based on
the American College of Rheumatology (ACR) 1987 re-
vised criteria [17] and active disease (≥6 tender/painful
joints (tender joint count (TJC)), 68-joint count) and ≥6
swollen joints (swollen joint count (SJC)), 66-joint count);
erythrocyte sedimentation rate (ESR) above the upper
limit of normal (local laboratory), or C-reactive protein
(CRP) >7 mg/L).
Key exclusion criteria were: severe, progressive or
uncontrolled renal, hepatic, haematological, gastrointes-
tinal, metabolic, endocrine, pulmonary, cardiac, neuro-
logical, or cerebral disease; current or past history of
rheumatic autoimmune diseases other than rheumatoid
arthritis (except Sjögren’s syndrome); history of any lym-
phoproliferative disorder, lymphoma, leukaemia, or lymph-
atic disease; and evidence of active infection, including
untreated or inadequately treated latent tuberculosis. Pa-
tients were discontinued from the study if two consecutive
clinical laboratory assessments met treatment discontinu-
ation criteria including: two sequential lymphocyte counts
<500 cells/mm3, two sequential haemoglobin measure-
ments <8.0 g/dL, or a decrease from baseline >30 %.Safety assessments
The primary endpoints were adverse event (AE) reports,
laboratory safety data and vital signs (irrespective of
whether these were reported as an AE). The incidence
and severity of all AEs, clinical laboratory tests and vital
signs were evaluated throughout the study.
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Efficacy endpoints included ACR20, ACR50 and ACR70
response rates (≥20/50/70 % improvement from baseline,
respectively, in both TJC and SJC, as well as in ≥3 of the
other five ACR components) [18]. Observed values and
changes from baseline in ACR component parameters
were assessed: TJC; SJC; Patient’s Assessment of Arth-
ritis Pain (visual analogue scale (VAS) range 0–100 mm);
Patient’s Assessment of Disease Activity/Arthritis (PtGA;
VAS); Physician’s Assessment of Disease Activity/Arthritis
(PGA; VAS); Health Assessment Questionnaire-Disability
Index (HAQ-DI; functional impairment in eight categories
scored from 0 (no difficulty) to 3 (unable to do) [19])
and CRP.
Other secondary endpoints included HAQ-DI and
Disease Activity Score (DAS). DAS was assessed using
DAS28-4(ESR) (composite index of four weighted vari-
ables: 28 TJC; 28 SJC; ESR; and PtGA), and DAS28-
3(CRP), which uses CRP instead of ESR and does not
include PtGA [20]. DAS28-4(ESR) and DAS28-3(CRP)
remission were defined as DAS28-4(ESR)<2.6 and
DAS28-3(CRP)<2.6, respectively [20–22]. Health-related
quality of life was assessed using the Short Form-36 (SF-
36). The SF-36 health survey (v.2) is a 36-item general
health status measure summarised as physical and mental
component scores [23].
All efficacy variables were analysed at weeks 2, 4, 8,
and 12, and then every 12 weeks (except SF-36, which
was assessed every 12 weeks throughout the study).Statistical analyses
Baseline values in this study were those of the qualifying
index study for all patients. Follow up and AE reporting
in this analysis is from the time of enrollment in the
LTE study; AEs occurring in the qualifying index studies
are not included. The full analysis set included all en-
rolled patients who had been part of an index study and
who received ≥1 dose of open-label study medication in
the LTE study; this was equivalent to the safety analysis
set. No formal hypothesis tests were conducted; descrip-
tive statistics were calculated for all safety data and effi-
cacy endpoints. Incidence rates (patients with events per
100 patient-years) were calculated as the number of
unique patients with an event (for that time period),
divided by the total exposure in that treatment group in
the pooled cohort, and multiplied by 100. Exposure was
censored at the time of the event.Protocol amendment
A protocol amendment on 9 March 2009 changed the
sample size of the study from 240 to 400 patients to
include patients from Study A3921040 [16], extended
the study duration, added the option of dose adjustmentto 10 mg BID after safety was demonstrated in phase II
studies, and removed dose options <5 mg.
Results
Patients
A total of 486 Japanese patients entered the LTE study:
195 (40.1 %) patients from the tofacitinib with back-
ground methotrexate index studies (113 patients from
phase II study A3921039 [13] and 82 patients from
phase III study A3921044 [12]) and 291 (59.9 %) pa-
tients from the tofacitinib monotherapy phase II index
study A3921040 [16] (Fig. 1). Of the patients who en-
rolled in the LTE study from the phase II index studies,
69 came from the placebo treatment arms. All patients
from the phase III index study had initiated tofacitinib
therapy during the index study. All patients enrolled in
the LTE study had initiated tofacitinib therapy within
14 days following the final visit of the index study. All
486 patients received ≥1 dose of study medication and
were evaluated for safety and efficacy. At baseline, most
patients were female (83.1 %) with a mean (range) dur-
ation of rheumatoid arthritis of 7.4 (0.4–45.0) years
(Table 1). The median (range) duration of tofacitinib
treatment in the LTE study was 1185 (5–2016) days
(1439.9 patient-years of exposure). Median (range) dur-
ation of treatment for the tofacitinib 5 mg BID group
was 1183 (5–2016) days (1111.7 patient-years of expos-
ure), and 1237 (137–1923) days for the tofacitinib 10 mg
BID group (328.2 patient-years of exposure). The numbers
of patients treated with tofacitinib for ≥1 year, ≥2 years,
≥3 years and ≥4 years (from the beginning of the LTE
study) were 423, 321, 278, and 83, respectively.
Safety
AEs are summarised in Tables 2, 3 and 4. Table 4
includes a summary of tofacitinib exposure and incidence
rates for safety events of special interest. The incidences of
patients with all-causality and treatment-related AEs were
97.9 % (n = 476) and 96.1 % (n = 467), respectively.
The most common treatment-emergent AEs were
nasopharyngitis (60.3 %; n = 293), herpes zoster (19.3 %;
n = 94), falls (14.6 %; n = 71), hyperlipidaemia (11.5 %;
n = 56) and hypertension (11.3 %; n = 55) (Table 2).
Most AEs (97.8 %) were mild or moderate in severity.
The overall incidence rate of AEs for all tofacitinib-
treated patients was 308.4 patients with events per
100 patient-years (95 % CI 281.3, 337.4; Table 4).
There were 139 patients (28.6 %; 10.7 patients with
events per 100 patient-years (95 % CI 9.0, 12.6); Table 4)
who had serious AEs (SAEs); 95 (19.5 %) patients had
treatment-related SAEs. Most SAEs resolved after tofaci-
tinib discontinuation. The most common AEs leading to
temporary discontinuation or dose reduction were naso-
pharyngitis (14.2 %; n = 69) and herpes zoster (10.9 %;
Fig. 1 Patient disposition. Evaluation of efficacy was based on patients remaining in the study (observed case analysis); accordingly, not all
patients were assessed through to the last observation visit. AE adverse event, BID twice daily






(n = 381) (n = 105) (n = 486)
Female, n (%) 318 (83.5) 86 (81.9) 404 (83.1)
Age in years, mean (SD) 53.5 (11.2) 49.3 (11.7) 52.6 (11.4)
Disease duration in years,
mean (range)
7.8 (0.4–38.0) 6.1 (0.4–45.0) 7.4 (0.4–45.0)
Tender joint counta, n 16.1 17.0 16.3
Swollen joint counta, n 13.4 14.3 13.6
HAQ-DIb score 1.23 1.22 1.23
DAS28-4(ESR) score 6.0 6.1 6.0
DAS28-3(CRP) score 5.0 5.2 5.1
ESR, mm/h 50.7 47.7 50.1
CRP, mg/L 24.1 27.4 24.9
Concomitant methotrexate,
n (%)
196 (51.4) 26 (24.8) 222 (45.7)
Concomitant systemic
corticosteroids, n (%)
256 (67.2) 80 (76.2) 336 (69.1)
Data are mean values except where indicated. Baseline values were those of
the index study
aScale 0–68 (tender/painful joints) and 0–66 (swollen joints); higher values
indicate greater levels of disease activity
bScale: 0–3; higher values indicate reduced physical function
BID twice daily, CRP C-reactive protein, DAS Disease Activity Score, ESR erythrocyte
sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index,
SD standard deviation
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incidence rate of herpes zoster (serious and non-serious)
was 7.4 patients with events per 100 patient-years (95 %
CI 6.0, 9.1; Table 4). Herpes zoster was the most common
AE leading to permanent discontinuation and this oc-
curred in 12.8 % of all herpes zoster cases (all consid-
ered treatment-related). Of the total 94 herpes zoster
cases, 14 (1.0 event per 100 patient-years (95 % CI
0.5, 1.6); Table 4) were reported as serious, including
one case of disseminated herpes zoster. There were
no aural or ophthalmic events. At the end of the
study, herpes zoster events had resolved in 88 pa-
tients, and were unresolved in 6 patients. Follow up
of these patients determined that herpes zoster had
resolved or was resolving in four patients and two
patients had post-herpetic neuralgia. The investigator
judged that there was no need for further follow up
to determine stabilised symptoms in these two pa-
tients. Thus, herpes zoster events had resolved or
were resolving in 92 patients; 2 patients had post-
herpetic neuralgia.
The proportion of patients with AEs was highest
between 0 and 6 months compared with subsequent
6-month periods (Table 3). Rates of discontinuation due
to AEs, SAEs and serious infections also generally
decreased over time (Table 3). The overall incidence rate
of serious infections was 3.3 patients with events per 100
patient-years (95 % CI 2.4, 4.4; Table 4). Nineteen malig-
nancies (excluding non-melanoma skin cancer) were
reported: gastric cancer (n = 3); breast cancer (n = 3);
ovarian cancer (n = 2); colon cancer (n = 2); lung cancer
Table 2 Summary of safety data up to 288 weeks of
observation in 486 patients
Variable Number (%)
All AEs 476 (97.9)
Serious AEs 139 (28.6)
Discontinuations due to AEs 118 (24.3)
Discontinuations due to serious AEs 75 (15.4)





Herpes zoster 94 (19.3)
Bronchitis 51 (10.5)





Tinea pedis 34 (7.0)
Oral herpes 33 (6.8)
Injury, poisoning or procedural complications
Fall 71 (14.6)
Contusion 49 (10.1)












Musculoskeletal and connective tissue disorders
Back pain 46 (9.5)
Investigations
Lymphocyte count decreased 38 (7.8)
White blood cell count decreased 27 (5.6)
Alanine aminotransferase increased 27 (5.6)
Respiratory, thoracic and mediastinal disorders
Upper respiratory tract inflammation 34 (7.0)
Cough 33 (6.8)
Table 2 Summary of safety data up to 288 weeks of
observation in 486 patients (Continued)
Skin and subcutaneous tissue disorders
Eczema 27 (5.6)
Blood and lymphatic system disorders
Anaemia 26 (5.3)
Treatment-emergent adverse events (AEs) affecting ≥5 % of patients in the
total population (all causalities) according to Medical Dictionary for Regulatory
Activities (MedDRA) System Organ Class and MedDRA (v16.1) preferred term.
Data are number (%)
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lymphoproliferative disorder, fallopian tube cancer, thyroid
cancer, oesophageal carcinoma, liposarcoma and transi-
tional cell carcinoma. For all tofacitinib-treated patients,
the incidence rate of malignancies (excluding non-
melanoma skin cancer) was 1.2 patients with events per
100 patient-years (95 % CI 0.7, 1.9; Table 4).
There were seven deaths (1.4 %; all with tofacitinib 5 mg
BID; 0.5 patients with events per 100 patient-years (95 %
CI 0.2, 1.0); Table 4). Reported causes of death (n = 1 for
each) were metastatic ovarian cancer, thrombotic throm-
bocytopenic purpura, metastatic small-cell lung cancer,
gastric adenocarcinoma, rectosigmoid cancer, rheumatoid
arthritis associated-pulmonary alveolar haemorrhage-
induced acute respiratory distress syndrome, and liposar-
coma. All deaths were considered treatment-related,
except the case of rheumatoid arthritis associated-
pulmonary alveolar haemorrhage-induced acute respira-
tory distress syndrome. Further details are provided in
Additional file 1: Table S1.
Changes in means of clinical laboratory parameters
were observed, with increases in haemoglobin serum
creatine, serum lipids (low-density lipoprotein choles-
terol, high-density lipoprotein cholesterol, and total
cholesterol), aspartate aminotransferase (AST), alanine
aminotransferase (ALT), and total bilirubin, and with
decreases in neutrophil, lymphocyte, and platelet counts.
With the exception of lymphocyte counts, mean overall
changes for clinical laboratory parameters generally oc-
curred within the first month of treatment in the index
study and then stabilised with longer treatment duration
in this study (Fig. 2).
While mean haemoglobin levels increased with tofa-
citinib treatment and remained elevated throughout the
study, a total of 6 out of 486 patients (1.2 %) had a
confirmed (two consecutive measurements) decrease
from baseline in haemoglobin that met potentially life-
threatening criteria (≥3 g/dL decrease from baseline or
haemoglobin ≤7 g/dL; Additional file 2: Figure S1). Of
these six patients, one had decreased haemoglobin
(below the lower limit of the reference range) at
baseline. Onset of decreased haemoglobin levels with
life-threatening severity ranged from 77 to 1,099 days
Table 3 Summary of adverse events and discontinuations over time in the total population
Month Post-month
48 (n = 99)0–6 6–12 12–18 18–24 24–30 30–36 36–42 42–48
(n = 486) (n = 455) (n = 430) (n = 405) (n = 343) (n = 309) (n = 293) (n = 207)
Adverse events 379 (78.0) 310 (68.1) 254 (59.1) 215 (53.1) 178 (51.9) 170 (55.0) 145 (49.5) 80 (38.6) 58 (58.6)
Discontinuations due to adverse events 26 (5.3) 19 (4.2) 21 (4.9) 7 (1.7) 13 (3.8) 8 (2.6) 12 (4.1) 1 (0.5) 7 (7.1)
Discontinuations due to serious adverse
events
15 (3.1) 16 (3.5) 10 (2.3) 7 (1.7) 6 (1.7) 6 (1.9) 8 (2.7) 1 (0.5) 6 (6.1)
Discontinuations due to serious infection
events
6 (1.2) 7 (1.5) 4 (0.9) 4 (1.0) 3 (0.9) 3 (1.0) 5 (1.7) 0 (0.0) 3 (3.0)
Data are number (%)
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The duration of decreased haemoglobin levels ranged
from 6 to 337 days. In all six patients, the decreased
haemoglobin either improved or returned to baseline
levels, with the discontinuation of the study drug (three
patients), or while remaining on the study drug (three
patients).
Most instances of neutropenia were mild in se-
verity (mild neutropenia: absolute neutrophil count
(ANC) ≥1.5 to <2 × 103/μL); no patients experienced
potentially life-threatening neutropenia (ANC <0.5 × 103/μL)
(Additional file 2: Figure S1b). Mean increases from baseline
lymphocyte counts were seen at week 2, followed by a
decline thereafter (Fig. 2b). Elevations ≥3 × upper limit of
the normal range in AST, ALT, and total bilirubin were
reported in 8 (1.65 %), 20 (4.12 %), and 1 (0.21 %) pa-
tients, respectively. No drug-induced liver injury was re-





Patients with events per 100 patient-years (95 % CI)
Adverse events 307.5 (277.0, 340.4
Serious adverse events 11.2 (9.2, 13.5)
Serious infections 3.2 (2.2, 4.5)
Herpes zoster (serious and non-serious) 7.1 (5.5, 8.9)
Serious herpes zoster 1.0 (0.5, 1.8)
Composite MACEa 0.4 (0.1, 1.0)
Gastrointestinal perforations 0 (0.0, 0.3)
All malignancy excluding NMSC 1.4 (0.8, 2.3)
Mortality 0.6 (0.3, 1.3)
aTotal exposure per group is less than for other safety events as composite major a
after 25 February 2009. Exposure was 1056.1, 325.0, and 1381.1 patient-years for to
respectively
NMSC non-melanoma skin cancerEfficacy
Evaluation of efficacy over time in this study was
based on efficacy responses observed in patients
remaining in the study (observed case analysis). The
ACR20 response rate at week 12 was 88.6 % and was
sustained throughout the study (Fig. 3a). An increase
in ACR20 response rate was apparent in patients who,
after not responding adequately to tofacitinib 5 mg
BID, had their dosage increased to 10 mg BID
(Additional file 3: Figure S2a). ACR50 and ACR70
response rates at week 12 were 65.5 % and 42.5 %,
respectively, and were also sustained throughout the
study (Figs. 3b and c). Changes from baseline in ACR
component scores over time are presented in
Additional file 4: Figure S3.
The proportion of patients achieving DAS28-4(ESR)-
defined remission was 25.5 % (n = 123/483) of patients
at week 2 and 49.6 % (n = 69/139) at week 204 (Fig. 3d).fety events of special interest
Tofacitinib All tofacitinib
10 mg BID
(N = 105) (N = 486)
328.2 1439.9
) 311.8 (255.0, 377.5) 308.4 (281.3, 337.4)
9.2 (6.1, 13.3) 10.7 (9.0, 12.6)
3.7 (1.9, 6.4) 3.3 (2.4, 4.4)
8.6 (5.6, 12.7) 7.4 (6.0, 9.1)
0.9 (0.2, 2.7) 1.0 (0.5, 1.6)
0.3 (0.0, 1.7) 0.4 (0.1, 0.9)
0 (0.0, 1.1) 0 (0.0, 0.3)
0.3 (0.0, 1.7) 1.2 (0.7, 1.9)
0.0 (0.0, 1.1) 0.5 (0.2, 1.0)
dverse cardiovascular event (MACE) adjudication applies only to data collected





Fig. 2 Mean laboratory parameters over time in the total population. Mean neutrophil count (a); lymphocyte count (b); platelet count
(c); haemoglobin (d); serum creatinine (e); low-density lipoprotein cholesterol (LDL-c) (f); high-density lipoprotein cholesterol (HDL-c) (g); and total
cholesterol (h). Baseline values were those of the phase II or phase III index study. SE standard error
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(DAS28-4(ESR)≤3.2 was 42.7 % (n = 206/483) at week 2
and 72.7 % (n = 101/139) at week 204. Mean CRP,
DAS28-3(CRP), ESR and DAS28-4(ESR), and rates of
DAS<2.6 and DAS≤3.2 over time are presented in
Additional file 5: Figure S4. Mean DAS28-4(ESR) for the
5 and 10 mg BID populations over time are presented in
Additional file 3: Figure S2b.
A decrease from baseline (−0.63) in mean HAQ-DI
score was observed at week 12 that was generally
sustained throughout the study (Fig. 3e and Additional
file 4: Figure S3f ). Mean HAQ-DI scores for both tofaci-
tinib groups over time are presented in Additional file 3:Figure S2c. The proportion of patients with clinically
meaningful improvement in HAQ-DI response (≥0.22)
was 77.5 % (n = 368/475) at week 12, and was sustained
throughout the study (77.7 % (n = 108/139) at week 204).
Improvements from baseline in the SF-36 scores were
observed at week 12 and sustained over 120 weeks. The
mean (standard error) changes from baseline at week 12
(n = 475) and week 192 (n = 180) were 7.92 (0.34) and
9.29 (0.57), respectively, in SF-36 physical component
scores, and 5.06 (0.54) and 2.38 (0.86), respectively, in
SF-36 mental component scores.
For all efficacy endpoints, results were similar when pa-





Fig. 3 Efficacy endpoints over time in the total population. American College of Rheumatology (ACR)20 (a); ACR50 (b); ACR70; (c); Disease Activity
Score in 28 joints (DAS28)-4(erythrocyte sedimentation rate (ESR))<2.6 (d); mean Health Assessment Questionnaire-Disability Index (HAQ-DI) (e).
Baseline values were those of the phase II or phase III index study. SE standard error
Yamanaka et al. Arthritis Research & Therapy  (2016) 18:34 Page 8 of 12tofacitinib as monotherapy versus those with background
methotrexate in their index study (data not shown).
Discussion
In this LTE study of up to 288 weeks' duration in Japanese
patients who had completed a previous phase II or phase
III index study, tofacitinib demonstrated a safety and
sustained efficacy profile that was generally consistent with
the profile seen in the phase II Japanese index studies [13,
16], phase III global studies [5, 9–12, 15] and the global
LTE pooled analysis (which included data from the study
reported here [14]). Incidence rates of AEs were higher in
the current study (308.4 events per 100 patient-years) than
in the global pooled analysis (154.5 events per 100 patient-
years). Nasopharyngitis was the most common AE ob-
served in both this Japanese study (60.3 %) and the global
pooled analysis (12.7 %), and also in the phase II Japanese
index studies (12 weeks in duration), although at a lower
incidence (8.3 % [13] and 10.2 % [16]) than reported in the
present study. The higher overall rate of AEs observed inthis study compared with the global LTE pooled analysis is
largely due to the higher rates of nasopharyngitis and her-
pes zoster in this study. In a pooled analysis of long-term
tocilizumab therapy in Japanese patients with rheumatoid
arthritis, the overall rate of AEs was 465.1 events per 100
patient-years, and the rate of nasopharyngitis was 64.1
events per 100 patient-years [24]. Furthermore, a high rate
of nasopharyngitis (68.0 %; 113.0 events per 100 patient-
years) was reported in a pooled analysis of etanercept
therapy in Japanese patients with rheumatoid arthritis [25].
Given that nasopharyngitis was the most frequently re-
ported AE in the tofacitinib global pooled analysis and that
higher rates of nasopharyngitis and overall AEs were also
observed in trials of biologic therapies in Japanese patients,
reporting bias or local seasonal effects may need to be
considered when interpreting the rate of nasopharyngitis
(and by extension the overall AE rate) in this LTE study in
Japanese patients.
The incidence rate of SAEs observed in this study
(10.7 patients with events per 100 patient-years) was
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tients with events per 100 patient-years) [14], lower than
that observed in a 5-year extension study of tocilizumab
(27.5 events per 100 patient-years) in Japanese patients
with rheumatoid arthritis [26], and similar to that re-
ported in the Registry of Japanese Rheumatoid Arthritis
Patients for Long-Term Safety (REAL) database, a 3-year
study of tumour necrosis factor inhibitors in Japanese
patients with rheumatoid arthritis (14.4 events per 100
patient-years) [27].
Incidence rates for serious infections in this study (3.3
events per 100 patient-years) were similar to those
reported in the tofacitinib global pooled analysis (3.1
events per 100 patient-years), the Japanese tocilizumab
LTE study (5.7 events per 100 patient-years) [26], and to
those in the REAL database of Japanese patients treated
with tumour necrosis factor inhibitors (5.5 events per
100 patient-years) [27].
In Japan, the incidence of herpes zoster in the general
population is estimated at 0.4 cases per 100 patient-
years based on a large-scale survey conducted in the
Miyazaki Prefecture [28]. In a large observational cohort
study, the incidence of herpes zoster in Japanese patients
with rheumatoid arthritis was 0.9 cases per 100 patient-
years [29]. The relevance of the herpes zoster incidence
rate in the Japanese population is highlighted by recent
risk-factor analyses that reported an increased incidence
rate of herpes zoster in Japanese and Korean patients
treated with tofacitinib [30]. It is unclear whether the
increased risk was due to genetic, cultural or environ-
mental differences between Eastern and Western popu-
lations, and close monitoring of herpes zoster infection
rates in Japanese tofacitinib-treated patients is war-
ranted. The incidence rate of all herpes zoster events
(serious and non-serious) was higher in the present
study (7.1 events per 100 patient-years with 5 mg BID
and 8.6 events per 100 patient-years with 10 mg BID)
than in the global pooled analysis (4.3 events per 100
patient-years) and also higher than reported in the
pooled analyses of tocilizumab therapy (2.3 events per
100 patient-years) [24] and etanercept therapy (2.9
events per 100 patient-years) [25]. The high rate of her-
pes zoster observed in the current study is consistent
with previous risk factor analysis that highlighted high
herpes zoster rates in Japanese populations [30]. The in-
cidence rate of malignancies (excluding non-melanoma
skin cancer) for tofacitinib-treated patients (1.2 events
per 100 patient-years) in this LTE study was comparable
with the rate in the global tofacitinib LTE study (1.0
event per 100 patient-years) [14] and with global rates
previously reported for biologic DMARDs (0.3–1.77
events per 100 patient-years) [31–34]. Gastric cancer is
the most frequently reported malignancy in Japan in the
general population [35] and, along with breast cancer,was the most commonly reported type of cancer in the
current study. Incidence rates of breast and lung cancer
were comparable to those reported in the global LTE
study. There was one case of non-melanoma skin cancer
(0.07 events per 100 patient-years) reported in this
Japanese study compared with 14 cases (0.5 events per
100 patient-years) of non-melanoma skin cancer in the
global LTE study.
In this study, deaths occurred in seven patients (1.4 %;
0.5 events per 100 patient-years), with all but one con-
sidered treatment-related. The observed rate of mortality
was the same as that observed in the tofacitinib global
pooled analysis [14], and consistent with that for studies
of other DMARDs. The mortality rates in LTE studies of
etanercept and adalimumab treatment were 0.8 and 0.7
events per 100 patient-years, respectively [36, 37]. No
deaths were reported in the open-label extension phase
of the infliximab study [38] and there were no deaths in
the tocilizumab study [26], though fewer patients were
enrolled in these studies than in the present study and,
accordingly, patient exposure was lower.
The proportion of discontinuations from the present
study (36.6 %) over 5.5 years was consistent with that re-
ported in the 5-year LTE study of tocilizumab monother-
apy in the Japanese population (34.3 %) [26].
With the exception of lymphocyte count, which de-
clined gradually following an initial increase from base-
line, changes in clinical laboratory parameters in this
study were generally consistent with observations from
the index studies [12, 13, 16] and with the global pooled
LTE analysis [14], where changes typically occurred dur-
ing the initial treatment period and then stabilised with
longer treatment duration over the course of the LTE
study. The proportion of patients who discontinued the
study due to abnormalities in clinical laboratory parame-
ters was small. Nevertheless, the contribution of negative
selection to the stabilisation of clinical laboratory param-
eters over time should be considered during the inter-
pretation of these results (i.e., patients who discontinued
the study no longer contributed to the mean laboratory
parameter values of the remaining total population).
Similarly, negative selection may also contribute to the
observed decrease in rates of AEs, SAEs and serious
infections with time. However, the rate of serious infec-
tions was consistent with that reported in Japanese pa-
tients with rheumatoid arthritis treated with tocilizumab,
where serious infection rates did not increase with long-
term tocilizumab exposure [24].
Improvements in all efficacy endpoints evaluated in
the current study were generally sustained over
288 weeks and few patients withdrew due to insufficient
clinical response. Improvements observed between
weeks 2 and 12 may have been due to the dose increases
(to 5 mg BID) for many patients who were receiving
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Similarly, following a lack of efficacy with tofacitinib
5 mg BID, some patients experienced an improvement
in clinical response following an increase in dose to
10 mg BID. However, it should be noted that the
strength of evidence for a benefit from tofacitinib dose
escalation is confounded by the fact that patients could
also change their background rheumatoid arthritis medi-
cation at any time during the study and by the uncon-
trolled nature of the observation. Overall, the sustained
efficacy data observed in this LTE study suggest that the
improvements in signs and symptoms of rheumatoid
arthritis and health-related quality of life achieved in the
tofacitinib phase II Japanese index studies are main-
tained in patients who remain on therapy, with nearly
75 % of patients achieving a DAS-defined low disease
activity state, and nearly half achieving DAS-defined
remission after 4 years.
A key benefit of the study design was that the protocol
permitted tofacitinib dose adjustments and the use of
concomitant medications, and therefore approximated
real-life treatment scenarios. Limitations of this LTE
study included the open-label, non-randomised design
with no control arm. In the absence of a comparator
arm, indirect comparisons of the results in this study
were made with external global and Japanese clinical
and observational studies. These comparator studies
may have different patient populations and study de-
signs; therefore, comparisons should be interpreted
accordingly. In addition, it is recognised that LTE studies
enroll only those patients who were eligible and com-
pleted the preceding randomised clinical trials, a patient
population in whom the agent is known to be efficacious
and well-tolerated. Although investigators could change
the tofacitinib and background therapy dosage to man-
age the safety and efficacy needs of the patients, this also
restricted the ability to compare the different tofacitinib
doses. Finally, reduced patient numbers after week 204
limited the data interpretation during the latter stages of
the study. The reduced number of patients after this
time point reflects the longer time between the begin-
ning of the index study and the end of the LTE study for
some patients, rather than a high rate of discontinuation
associated with this period of the study.
Conclusion
In conclusion, tofacitinib 5 mg and 10 mg BID with or
without background methotrexate therapy demonstrated
a safety profile consistent with that previously reported
in the index studies and showed sustained efficacy up to
5.5 years in Japanese patients with active rheumatoid
arthritis. The risk of herpes zoster appears to be higher
in Japanese patients treated with tofacitinib than in the
global population.Additional files
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